Autopsy report · NCT00803868
Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia
Cause of deathOther, also safety
“The DSMB recommended that the study be stopped as a result of concerns regarding safety and intolerability and insufficient evidence of efficacy.”
Life of this trial
- Registered 5 months before it started.
- Ran for about 1 year before it stopped.
- 28 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2, Phase 3
- Sponsor
- University of South Florida
- Sponsor type
- University, hospital or other
- Conditions
- Friedreich's Ataxia
- Interventions
- varenicline; placebo
- Participants
- 28
- Sites
- 2
- Countries
- United States
Trials that died the same way
- Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
“The independent DSMB recommended that the study be stopped for futility following interim efficacy analysis.” - Estrogen Replacement to Reduce Risk of Neurologic Injury After Coronary Artery Bypass Graft Surgery
“DSMB stopped the study based on conclusion of likely futility of treatment on the primary outcome.” - ATG Plus Low-dose PT-Cy for GVHD Prevention
“DSMB recommended halting the study owing to futility after the first interim analysis in August 2024.” - Stroke With Transfusions Changing to Hydroxyurea
“The study has been stopped due to safety and futility concerns.” - A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
“This study was terminated due to limited efficacy and not due to safety reasons”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.